Early safety concerns accompanied Merck’s molnupiravir, the first potential oral COVID-19 therapy 

The antiviral molnupiravir appears to be destined to become the first oral treatment for COVID-19. Merck and its partner Ridgeback Biotherapeutics intend to file for emergency use authorization after announcing that the drug appears to reduce the risk of hospitalization or death by about 50%. One potential hurdle for the drug is whether unvaccinated individuals … Continue reading Early safety concerns accompanied Merck’s molnupiravir, the first potential oral COVID-19 therapy